登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06958705,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 80 岁;性别:不限
登记记录的入选字段
NYHA functional class ≤ 2.
入选标准第 18 条
2. Active malignancy requiring systemic therapy, other than CLL, with the exception of: adequately treated in situ carcinoma of the cervix uteri; adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
排除标准第 2 条
3. Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drug.
排除标准第 3 条
11. Received other therapeutic agents for CLL/SLL during BTK inhibitor treatment prior to enrollment.
排除标准第 11 条
13. Received strong CYP3A inhibitors or strong CYP3A inducers within 7 days of starting venetoclax.
排除标准第 13 条
15. Prior treatment with venetoclax or other Bcl-2 inhibitor.
排除标准第 15 条
6. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
入选标准第 6 条
Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for patients with Gilbert's disease;
入选标准第 8 条
Serum creatinine clearance of ≥ 50 ml/min (calculated or measured);
入选标准第 9 条
ALT and AST ≤ 3.0 × ULN, unless clearly due to disease involvement.
入选标准第 10 条
Platelet count of greater than 50,000/µl, with no platelet transfusion in prior 2 weeks;
入选标准第 12 条
ANC ≥ 1000/µl in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by ≥ 80% CLL in marrow;
入选标准第 13 条
Hemoglobin ≥ 8g/dL.
入选标准第 14 条
7. Known HIV positive.
排除标准第 7 条
8. Active hepatitis B infection (defined as the presence of detectable HBV DNA or HBe antigen). Patients who are HBsAg positive or HBcAb positive are eligible, provided HBV DNA is negative. These patients must have monthly monitoring of HBV DNA for the duration of the study.
排除标准第 8 条
9. Active hepatitis C, defined by the detection of hepatitis C RNA in plasma by PCR.
排除标准第 9 条
6. Females who are pregnant or lactating.
排除标准第 6 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06958705,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
1. Age: 18-80 years-old. 2. Patients must have a diagnosis of CLL/SLL. 3. Detectable MRD by flow cytometry (10\^-4 sensitivity) in the peripheral blood. 4. Patients who are on BTK inhibitor monotherapy for more than 6 months. This study includes patients who are taking one of the following BTK inhibitors: ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib. 5. Patients need to have a response of at least PR (CR/PR) to BTK inhibitor monotherapy. 6. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. 7. Patients must have adequate renal and hepatic function: Serum bilirubin ≤ 1.5 × upper limit of normal (ULN) or ≤ 3 × ULN for patients with Gilbert's disease; Serum creatinine clearance of ≥ 50 ml/min (calculated or measured); ALT and AST ≤ 3.0 × ULN, unless clearly due to disease involvement. 8. Adequate bone marrow function: Platelet count of greater than 50,000/µl, with no platelet transfusion in prior 2 weeks; ANC ≥ 1000/µl in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by ≥ 80% CLL in marrow; Hemoglobin ≥ 8g/dL. 9. Adequate cardiac function, as assessed by: Absence of uncontrolled cardiac arrhythmia; Echocardiogram demonstrating LVEF ≥ 35%; NYHA functional class ≤ 2. 10. Ability to provide informed consent and adhere to the required follow-up.排除标准:Exclusion Criteria:
1. Richter transformation. 2. Active malignancy requiring systemic therapy, other than CLL, with the exception of: adequately treated in situ carcinoma of the cervix uteri; adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent. 3. Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drug. 4. Grade 3 or 4 hemorrhage within the past 3 weeks. 5. Uncontrolled active infections (viral, bacterial, and fungal). 6. Females who are pregnant or lactating. 7. Known HIV positive. 8. Active hepatitis B infection (defined as the presence of detectable HBV DNA or HBe antigen). Patients who are HBsAg positive or HBcAb positive are eligible, provided HBV DNA is negative. These patients must have monthly monitoring of HBV DNA for the duration of the study. 9. Active hepatitis C, defined by the detection of hepatitis C RNA in plasma by PCR. 10. Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy > 20 mg prednisone daily or equivalent, within 7 days of starting venetoclax. 11. Received other therapeutic agents for CLL/SLL during BTK inhibitor treatment prior to enrollment. 12. Concurrent use of warfarin or equivalent vitamin K inhibitor or other oral anticoagulant treatment. 13. Received strong CYP3A inhibitors or strong CYP3A inducers within 7 days of starting venetoclax. 14. Consuming grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting venetoclax. 15. Prior treatment with venetoclax or other Bcl-2 inhibitor. 16. Malabsorption syndrome or other condition that precludes enteral route of administration.
引自 ClinicalTrials.gov, NCT06958705, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06958705,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。